Search

Displaying results 5161 - 5170 of 10000 in total
  1. Drug

    SYN-101

    go.drugbank.com/drugs/DB05958
    Experimental

    SYN101 is comprised of an immune cell specific antibody linked to an ALK5 inhibitor payload to selectively block TGF-b signalling in immune cells. … SYN-101 is an investigational antibody-drug conjugate developed for the treatment of cancer.

  2. Drug

    Pipendoxifene

    go.drugbank.com/drugs/DB05414
    Investigational

    Pipendoxifene is a new 2-phenyl indole selective estrogen receptor modulators (SERM )that exhibits an excellent preclinical pharmacological profile and was selected for further development as a treatment … ER modulator, ERA-923(Pipendoxifene) is a estrogen receptor modulator being evaluated for the treatment of breast cancer.

  3. Drug

    VB2-011

    go.drugbank.com/drugs/DB05411
    Experimental

    VB2-011 is an antibody developed as an anti-cancer treatment. According to some preclinical studies, it has a potential to inhibit tumour growth in various cancers including lymphoma and melanoma.

  4. Drug

    Zeaxanthin

    go.drugbank.com/drugs/DB11176
    ApprovedInvestigational

    Zeaxanthin is a most common carotenoid alcohols found in nature that is involved in the xanthophyll cycle. … As a coexistent isomer of lutein, zeaxanthin is synthesized in plants and some micro-organisms.

  5. Drug

    alpha-Conotoxin VC 1.1

    go.drugbank.com/drugs/DB05724
    Experimental

  6. Drug

    Anagliptin

    go.drugbank.com/drugs/DB12417
    Investigational

    Anagliptin is under investigation for the treatment of LDL Cholesterol, Coronary Disease, Diabetes Mellitus, Glycosylated Hemoglobin, and Dipeptidyl-Peptidase 4 Inhibitors.

    Categories: DPP-IV Inhibitors
  7. Drug

    Aprindine

    go.drugbank.com/drugs/DB01429
    Experimental

    Aprindine is a cardiac depressant used in arrhythmias.

    Categories: Antiarrhythmics, Class I, Antiarrhythmics, Class Ib
  8. Drug

    XTL-6865

    go.drugbank.com/drugs/DB06058
    Investigational

    It is being developed to prevent HCV re-infection following a liver transplant and for the treatment of chronic HCV disease. … XTL-6865 is a combination of two fully human monoclonal antibodies (Ab68 and Ab65) against the hepatitis C virus E2 envelope protein.

  9. Drug

    Opaganib

    go.drugbank.com/drugs/DB12764
    Investigational

    [L27436] This drug has potential anticancer, anti-inflammatory, and antiviral activities, with potential applications in oncology, inflammation, the gastrointestinal system, and COVID-19. … Opaganib, also known as ABC294640, is a selective [sphingosine kinase-2 (SK2)](https://go.drugbank.com/polypeptides/Q9NRA0) inhibitor that is orally administered.

  10. Drug

    Aranidipine

    go.drugbank.com/drugs/DB09229
    Experimental

    [A31895] It was developed by Maruko Seiyaku, introduced by Taiho and launched in Japan in 1997.[T88] … It is a calcium antagonist with the formula methyl 2-oxopropyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylate.